ArticleJAMA network open2025
Incidence of Pancreas and Colorectal Adenocarcinoma in the US.
Article in JAMA network open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Chemokine receptor CXCR2 and plasminogen activator inhibitor-1 expression in colorectal adenocarcinoma are associated with prognostic features.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Article
- Article
- Adenomatous Polyposis Coli Gene Polyposis-Related Syndromes.The American journal of gastroenterology · 2026Review
- Trends in Pancreatic Cancer Incidence, Mortality and Net Survival: A Population-Based Analysis in Zurich (Switzerland), 1981-2021.Journal of gastrointestinal cancer · 2026Article
- LC-MS/MS-based metabolomics analysis and experimental verification reveal the mechanism of Dahuang Mudan Decoction inhibition with the proliferation of colorectal cancer cells.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Catching pancreatic cancer early: the promise of affordable biomarkers to regularly screen high-risk individuals.Translational gastroenterology and hepatology · 2026Article
- Informing development of brain cancer therapies within "preclinical trials" using ex vivo patient tumors.Advanced drug delivery reviews · 2026Review
- Focal adhesion assembly and cell migration require myoferlin in PDAC cell lines.Scientific reports · 2025Article
- Early Detection of Pancreatic Cancer.Visceral medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Importance: Pancreas cancer is the seventh leading cause of cancer death and colorectal cancer is the second leading cause of cancer death worldwide, with increasing incidence for both, particularly in younger age cohorts. Objective: To report updated incidence trends for pancreas and colorectal adenocarcinomas in the US, with the specific intent of examining the annual percentage changes (APCs) in younger age groups. Design, Setting, and Participants: This retrospective cohort study used data from the Surveillance, Epidemiology, and End Results database to examine incidence trends from 2000 to 2021. Individuals with pancreatic and colorectal adenocarcinoma were included. Data through 2021 were released on April 17, 2024. Data analysis occurred from December 4, 2024, to February 1, 2025. Main Outcomes and Measures: Yearly incidence rates were obtained for pancreatic and colorectal adenocarcinoma. Temporal trends of pancreas adenocarcinoma incidence rates by covariates were measured by APC and 95% CIs. Results: From 2000 to 2021, 275 273 cases of pancreas adenocarcinoma were identified (142 633 male patients [51.8%]; 239 840 patients [87.1%] aged ≥55 years). The APC for pancreatic adenocarcinoma was 4.35 (95% CI, 2.03 to 6.73) in the group aged 15 to 34 years, which was statistically significantly higher than the APCs of 1.74 (95% CI, 1.59 to 1.89) (P = .007) for the group aged 55 years and older and 1.54 (95% CI, 1.18 to 1.90) (P = .004) for the group aged 35 to 54 years. A total of 1 215 200 cases of colorectal cancer were identified (641 776 male patients [52.8%]; 976 716 patients [80.4%] aged ≥55 years). The APC for colorectal adenocarcinoma was -3.31 (95% CI, -3.54 to -3.08) for the group aged 55 years and older, which was statistically significantly lower than the APCs of 1.75 (95% CI, 1.08 to 2.42) (P = .001) for the group aged 15 to 34 years and 0.78 (95% CI, 0.51 to 1.06) (P = .002) for the group aged 35 to 54 years. Conclusions and Relevance: The findings of this cohort study suggest that the incidence of pancreatic adenocarcinoma has increased among all age groups, whereas that of colorectal adenocarcinoma has increased among younger age groups. Clinicians should be aware of this trend when evaluating younger patients with relevant symptoms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.